Creative Medical Technology Holdings (CELZ) Return on Capital Employed (2011 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Return on Capital Employed of 87.15% for Q1 2026, down 18.0% year-over-year from 106.28% in Q1 2025, and up 7.12% quarter-over-quarter from 93.84% in Q4 2025.
Creative Medical Technology Holdings (CELZ) Return on Capital Employed (2011 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Return on Capital Employed for 16 consecutive years, with 87.15% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 18.0% year-over-year to 87.15%; the TTM figure through Mar 2026 stood at 87.15% (down 18.0% YoY), while the FY2025 annual figure was 88.33%, down 1966.0% from the prior year.
- Return on Capital Employed advanced to 87.15% in Q1 2026 per CELZ's latest filing, from 93.84% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 24.12% in Q3 2022 and bottomed at 97.83% in Q3 2025.
- Historically, Return on Capital Employed has averaged 67.87% across 5 years, with a median of 71.94% in 2024.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 24732 bps — and 2023, when it jumped 853 bps.
- Creative Medical Technology Holdings' Return on Capital Employed stood at 58.52% in 2022, then climbed by 15 bps to 49.99% in 2023, then tumbled by 78 bps to 89.04% in 2024, then retreated by 5 bps to 93.84% in 2025, then climbed by 7 bps to 87.15% in 2026.
- Business Quant data shows CELZ's Return on Capital Employed at 87.15% in Q1 2026, 93.84% in Q4 2025, and 97.83% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | -86.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -86.54% |
| Mar 31, 2026 | -87.15% |
| Dec 31, 2025 | -93.84% |
| Sep 30, 2025 | -97.83% |
| Jun 30, 2025 | -79.47% |
| Mar 31, 2025 | -86.98% |
| Dec 31, 2024 | -89.04% |
| Sep 30, 2024 | -79.21% |
| Jun 30, 2024 | -71.94% |
| Mar 31, 2024 | -57.59% |
| Dec 31, 2023 | -49.99% |
| Sep 30, 2023 | -78.50% |
| Jun 30, 2023 | -67.25% |
| Mar 31, 2023 | -60.73% |
| Dec 31, 2022 | -58.52% |
| Sep 30, 2022 | -24.12% |
| Jun 30, 2022 | -32.43% |
| Mar 31, 2022 | -39.29% |
| Dec 31, 2021 | -50.83% |
| Sep 30, 2021 | 126.43% |